All Shared Posts

New UTI Vaccine Is Pineapple-Flavoured, Oral-Based, And May Prevent Recurring UTIs For Up To 9 Years A pineapple-flavoured UTI vaccine could prevent recurrent urinary tract infections (UTIs) and fight treatment-resistant bacteria. However, it has yet to be cleared of widespread usage in Australia, the US, and the UK. The MV140 vaccine can alleviate the risk of antibiotic resistance in UTIs treated with commonly used antibiotics. The vaccine is orally applied under the tongue, where the stimulus to the oropharyngeal system can trigger a strong immune response in the bladder. Various studies on MV140 have demonstrated its potential benefits to respondents with recurrent UTIs. In 2022, women who received the vaccine only had zero to one instance of UTIs in nine months. Meanwhile, recent results from a long-term study revealed that 54% of their participants (72 women and 17 men) remained UTI-free for nine years, while the remainder only had fewer and less severe symptoms. Experts suggest that MV140 should now be tested on more complex populations, such as chronic UTIs, children, and immunocompromised individuals. As of writing, MV140 has yet to be approved in most countries, and there is yet to be an application for the vaccine in Australia’s Therapeutic Goods Administration. However, doctors in Australia can apply to prescribe it to specific patients via the special access scheme or to become an authorised prescriber to multiple patients. The MV140 vaccine is another potential solution, among others such as a rapid-dissolving tablet and a directly-administered cellular vaccine, that also aims to alleviate UTI symptoms without resorting to antibiotic treatments. Urinary tract infections are among the most common bacterial infections, with more than 50% of women and 20% of men having a UTI at some point in their lifespan. Recurring instances of the infection may also occur in patients, with symptoms appearing at least two times in six months or at least three times in a year.

Residents, Travellers Urged To Stay Alert As MVE Activity Is Detected In Western Australia The WA Health Department urges residents and travelers in Western Australia to protect themselves from mosquito bites. The advisory comes after the Murray Valley encephalitis (MVE) virus was detected in mosquitoes in the Pilbara and Kimberley regions. According to the WA Health Department, there are no cases of MVE among Western Australia citizens. While the increase in possible mosquito-borne virus activity is not uncommon in the region at this time of the year, vigilance towards health remains key in avoiding health risks. Moreover, while the risk of infection and suffering symptoms of MVE remain low, Australians should seek immediate medical attention should they feel unwell. Symptoms of MVE include dizziness, drowsiness, fever, headache, nausea, and stiff neck. To avoid mosquito bites, Australians are encouraged to avoid outside in peak mosquito hours such as at dawn and early evening. Should there be a need to go outside, wearing long and loose-fitting clothes while also applying mosquito repellent is advisable. Homes can be made more mosquito-repellent by keeping grass short around the house and installing insect screens on openings such as doors and windows.

Aussies Encouraged To Make Covid-19 Plans With GP If They Are Vulnerable To Symptoms Most Australians at a higher risk of Covid-19 don’t have plans with their GP if they are affected by symptoms, according to a new study. As per Pfizer, 74% of Australians who are more vulnerable to COVID-19 have yet to create a medical plan on how they can recover should they experience symptoms. Experts from non-profit Street Side Medics urge Australians to speak with their GPs and other appropriate medical professionals to ensure they are cared for, especially if they are medically vulnerable. Australians may become at a higher risk of COVID-19 symptoms if they are: over 50 years old, have existing health conditions such as heart disease, respiratory conditions, diabetes, and if they are immunocompromised. While Australians are eligible for antiviral medicines to help alleviate COVID-19 effects, they must take them as soon as they test positive for COVID-19 and within five days of the first signs of symptoms. This helps ensure they are eligible for such medication and secure their availability should the need arise.

Prepare for Flu, RSV, and COVID: When's the Best Time for Vaccination? As flu, RSV, and COVID cases are anticipated to surge soon, it's crucial to consider vaccination timing. Cooler weather is approaching, and along with it come unwanted guests: COVID, influenza, and RSV. Experts are warning of a potentially severe flu season, with concerns over low vaccine uptake and increased hospitalisations. Here's what you need to know: Influenza The 2024 flu season could surpass the previous year, lacking herd immunity due to past isolation. Increased international travel may introduce influenza strains from the northern hemisphere. Children, especially those aged five to nine, are at risk of hospitalisation. Vaccination is recommended for everyone over six months of age. RSV Respiratory syncytial virus (RSV) infections are common, particularly in infants. RSV can lead to serious complications, including pneumonia. Nirsevimab, a long-acting antibody, has been approved to reduce RSV infections by 75% for up to five months. Some states offer free RSV immunisation programs for infants and children. COVID-19 COVID-19 cases are expected to rise concurrently with flu and RSV peaks. Dual infections with RSV and COVID-19 could lead to increased severity. Booster recommendations vary by age and immunocompromised status. Annual boosters are advised for most adults, with six-monthly boosters for those over 65 or severely immunocompromised. It's essential to stay informed and discuss vaccination options with healthcare providers to protect against these respiratory illnesses.